Sumitomo Mitsui Trust Group
FATE icon

Sumitomo Mitsui Trust Group’s Fate Therapeutics FATE Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-907,930
Closed -$9.16M – 1163
2022
Q4 		$9.16M Sell
907,930
-380,928
-30% -$7.15M 0.01% 791
2022
Q3 		$28.9M Buy
1,288,858
+18,293
+1% +$529K 0.02% 634
2022
Q2 		$31.5M Buy
1,270,565
+7,699
+0.6% +$212K 0.02% 636
2022
Q1 		$49M Buy
1,262,866
+20,023
+2% +$775K 0.03% 543
2021
Q4 		$72.7M Sell
1,242,843
-3,727
-0.3% -$211K 0.04% 434
2021
Q3 		$73.9M Buy
1,246,570
+214,490
+21% +$16.8M 0.05% 427
2021
Q2 		$89.6M Buy
1,032,080
+470,485
+84% +$37.9M 0.05% 381
2021
Q1 		$46.3M Buy
561,595
+23,931
+4% +$2.29M 0.03% 564
2020
Q4 		$48.9M Buy
537,664
+55,238
+11% +$3.43M 0.03% 543
2020
Q3 		$19.3M Sell
482,426
-49,778
-9% -$1.74M 0.01% 695
2020
Q2 		$18.3M Sell
532,204
-393,805
-43% -$11.7M 0.01% 691
2020
Q1 		$20.6M Buy
926,009
+106,199
+13% +$2.69M 0.02% 626
2019
Q4 		$16M Sell
819,810
-20,620
-2% -$327K 0.01% 698
2019
Q3 		$13.1M Buy
840,430
+331,589
+65% +$6.36M 0.01% 700
2019
Q2 		$10.3M Buy
+508,841
New +$9.17M 0.01% 718

Other funds holding FATE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group's FATE Position: Q1 2023 in Review

Sumitomo Mitsui Trust Group sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 907,930 shares — an estimated $9.16M sold.

Sumitomo Mitsui Trust Group first reported a position in FATE in Q2 2019 and held it in 15 quarters. The position peaked at $89.6M in Q2 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Sumitomo Mitsui Trust Group reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 907,930 Fate Therapeutics shares in Q1 2023, an estimated $9.16M.
  • Sumitomo Mitsui Trust Group first reported a position in Fate Therapeutics in Q2 2019 and held it in 15 quarters.
  • Sumitomo Mitsui Trust Group's Fate Therapeutics position peaked at $89.6M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2023, filed 27 Apr 2023.